Evidence map›Paper›PMID 12844465›Full record

ReviewCurrent hypertension reports2003

Management of diabetic and hypertensive cardiovascular disease.

Edward D Frohlich, James R Sowers

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hypertension reports, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Edward D FrohlichOchsner Clinic Foundation, 1516 Jefferson Highway, New Orleans, LA 70121, USA. efrohlich@ochsner.org
James R Sowers

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The simultaneous occurrence of essential hypertension and diabetes mellitus is exceedingly common. In recent years the treatment of the cardiovascular and renal complications has not only become more specific but more effective. The evidence-based medicine data have been provided through many large multicenter studies and strongly support the promise not only of effective treatment in retarding the progression of target-organ involvement, but also the potential of reversal. These dramatic therapeutic improvements have been made possible by wedding the involved pathophysiologic disease mechanisms with the actions of pharmacologic agents. Inherent in this concept is the promise of retarding the development of the cardiovascular and renal morbid events and also reducing their associated mortal endpoints.

Indexed as

Adrenergic alpha-AntagonistsAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsCalcium Channel BlockersDiabetic AngiopathiesDiabetic NephropathiesDiureticsHumansHypertensionMineralocorticoid Receptor AntagonistsAdrenergic alpha-AntagonistsAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsCalcium Channel BlockersDiureticsMineralocorticoid Receptor Antagonists

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.